News
NVO stock climbs nearly 6% in August as Lilly's oral obesity candidate setback pivots investor sentiment toward the former's ...
The Mounjaro KwikPen, a multi-dose, prefilled device for single-patient use, is designed for convenient self-administration.
Eli Lilly on Wednesday launched the easy-to-use injector pen of its blockbuster weight-loss drug Mounjaro for 14,000 rupees ...
Novo Nordisk's growth in diabetes and obesity care makes it a strong buy. Click here for a full investment analysis of NVO ...
Attorney General Paxton argues that the company’s programs and offerings were essentially bribes and resulted in millions in ...
Despite posting record Q2 growth for its blockbuster weight loss and diabetes drug tirzepatide, Eli Lilly is facing legal ...
Insmed received FDA clearance for the first treatment for a chronic lung disease, opening the way to what could be a ...
Response Pharmaceuticals has shared phase 2 data in post-GLP-1 patients, linking its ex-Sanofi asset to reductions in ...
Each KwikPen contains four doses, designed for single-patient use, and is priced between Rs14,000 and Rs 27,500 per month ...
Eli Lilly has rolled out a prefilled pen version of its weight-loss drug Mounjaro at the same price as vials, aiming to ...
Eli Lilly (LLY) stock in focus as the company launches Mounjaro Kwikpen in India, intensifying competition with Novo ...
Eli Lilly has launched Mounjaro in KwikPen, a prefilled pen for weekly administration, in India to treat type 2 diabetes and ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results